Historically, the venture capital industry has overlooked weight-loss solutions – but the advent of GLP-1 medications has changed the landscape rapidly over the past few years. Dennis McWilliams shares his perspective on the shift towards these treatments in a new Bloomberg article, highlighting recent developmental efforts to produce options with more tolerable side effects. Additionally, as patients often regain weight after stopping these drugs, companies are looking to create new strategies in managing this transition without rebounding. While it seems that every major pharma company now has their own obesity strategy, Dennis provides thoughts on where to invest in what has become a crowded market. https://lnkd.in/eHSqdsAG
SANTÉ’s Post
More Relevant Posts
-
Read Luca Borrelli’s latest blog post to find out which key challenges big pharma wants to address when acquiring mid-sized biotechs. #PwCDeals #ValueCreation #IndustryTrends #DealsTrends #MandA2024
-
Read Luca Borrelli’s latest blog post to find out which key challenges big pharma wants to address when acquiring mid-sized biotechs. #PwCDeals #ValueCreation #IndustryTrends #DealsTrends #MandA2024
Health industry M&A 2024 outlook
pwcch.smh.re
-
Director, Investor Reporting / Capital Markets & Accounting Advisory Services , PwC Switzerland
Read Luca Borrelli’s latest blog post to find out which key challenges big pharma wants to address when acquiring mid-sized biotechs. #PwCDeals #ValueCreation #IndustryTrends #DealsTrends #MandA2024
Health industry M&A 2024 outlook
pwcch.smh.re
-
Senior Manager | Deals | Corporate Finance / M&A | Consumer Goods and Healthcare Sector | PwC Switzerland
Read Luca Borrelli’s latest blog post to find out which key challenges big pharma wants to address when acquiring mid-sized biotechs. #PwCDeals #ValueCreation #IndustryTrends #DealsTrends #MandA2024
Health industry M&A 2024 outlook
pwcch.smh.re
-
Partner | Head of Deals Strategy & Sustainability in Deals | PwC Switzerland | Atlantic Rower
Read Luca Borrelli’s latest blog post to find out which key challenges big pharma wants to address when acquiring mid-sized biotechs. #PwCDeals #ValueCreation #IndustryTrends #DealsTrends #MandA2024
Health industry M&A 2024 outlook
pwcch.smh.re
-
The FT Live US Pharma & Biotech Summit is the top gathering of #biopharma leaders, regulators, investors, and scientists to share unique insights about the year ahead and discuss the most important trends affecting the industry, and the country. See the list of companies that are attending: https://bit.ly/44kazUu Can you afford to miss out? https://bit.ly/49yZNKO #FTPharma Endpoints News
US Pharma and Biotech Summit 2024 - A Financial Times Live Event
uspharma.live.ft.com
-
The U.S. share of global biopharma companies has decreased from 47% to 39% between 2017 and 2024, while China's share has surged from 5% to 16%, highlighting a significant shift in the biotech landscape. This decline underscores the urgent need for an innovation-friendly regulatory environment to attract investment and drive advancements in healthcare. If current policies continue to stifle the biotech ecosystem, we risk losing our competitive edge and patient access to groundbreaking therapies to countries that prioritize supportive frameworks for drug development. #Biotech
We Must Win The Race For Global Biotech Innovation
social-www.forbes.com
-
J.P. Morgan's #China Healthcare guru Yang Huang, PhD, CFA recently took investors on a China-wide tour of Biotech, AI for drug discovery, Medtech, Pharma, and Private hospital companies. Biotech with global potential was a key segment highlight, with many investors looking for potential bottoming of CXO stocks. More insights from Yang below...
-
Partner | Deals | Helping Pharma Life Science and Private Equity to create value through M&A
Read my latest blog post to find out which key challenges big pharma wants to address when acquiring mid-sized biotechs. #PwCDeals #ValueCreation #IndustryTrends #DealsTrends #MandA2024 https://lnkd.in/eQvc-u-u
Health industry M&A 2024 outlook
pwc.ch
-
Providing the best Talent and Services for your team globally within the Life Science / Biotech sector
Big Pharma holds $1 trillion war chest for biotech deals, but needs Fed's help Big Pharma is sitting on a mountain of cash ($1 trillion!) waiting to invest in innovative new biotech therapies The catch? They need the Federal Reserve to lower interest rates to make those deals happen Here's the breakdown: -Pharma companies are facing a patent cliff, with many of their drugs losing exclusivity ⏰ -They need fresh blood (new drugs!) from innovative biotech companies to stay competitive -Biotech companies are struggling with financing, despite strong innovation So, what's the solution? A Fed rate cut could unlock the floodgates for biotech investment Even without a rate cut, EY, the report's author, is cautiously optimistic: Strong innovation in biotech will help the sector thrive in the long run Strategic alliances with pharma companies are providing valuable funding What are your thoughts? Will the Fed come to the rescue of biotech? #biotech #pharma #investment #healthcare #federalreserve
CEO @GSI | RePhil Capital | Board Exec | Impact Investor InspiringFiftyTopFifty DeepTech
2moWouter van Furth